Diabetes medicine metformin recalled due to high level of anti-cancer agent


The diabetes drug metformin hydrochloride has been recalled because it contains excessive levels of a carcinogen, the US Food and Drug Administration said this week.The drug’s maker, Marksans Pharma Limited, has expanded a recall originally announced in June to now include an additional 76 unexpired lots of the drug.

The recalled drugs are marketed as “extended-release tablets” under the brand name Time-Cap Labs, Inc.

The drug helps lower blood sugar levels in people with type 2 diabetes.

But the recalled product contained an unacceptable level of N-Nitrosodimethylamine, which is considered a probable human carcinogen.

“Marksans carried out tests with N-Nitrosodimethylamine (NDMA) on marketed batches identified as unexpired and observed that the NDMA content of certain batches exceeds the acceptable daily intake limit (ADI) of 96 ng / day”, the FDA pointed out in its announcement.

“Consequently, as a precaution, 76 additional lots are being recalled.

The booster applies to metformin tablets between 500 mg and 750 mg.

The 500 mg tablets are debossed with “101” on one side; the 750 mg tablets are debossed with “102” on one side, the agency said.

The FDA advises users to continue taking the recalled tablets until a healthcare practitioner offers a replacement or alternative treatment option.

“It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their healthcare professional,” the FDA said in a statement.

Consumers “should contact their doctor or health care provider if they have encountered any problems that may be related to taking or using this medicine.”


Please enter your comment!
Please enter your name here